Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence

Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved by anchoring membrane-bound bioactive interleukin 2 (IL2) and enriching T cell-promoting costimu...

Full description

Saved in:
Bibliographic Details
Published in:Science advances 2023-04, Vol.9 (17), p.eade0625-eade0625
Main Authors: Wu, Kerui, Lyu, Feng, Wu, Shih-Ying, Sharma, Sambad, Deshpande, Ravindra Pramod, Tyagi, Abhishek, Zhao, Dan, Xing, Fei, Singh, Ravi, Watabe, Kounosuke
Format: Article
Language:English
Subjects:
Animals
Humans
Immunotherapy
Immunotherapy, Active
Interleukin-2
Mice
Neoplasms - therapy
T-Lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved by anchoring membrane-bound bioactive interleukin 2 (IL2) and enriching T cell-promoting costimulatory factors on the surface of the dendritic cell-derived small extracellular vesicles. This nanovesicle also displays major histocompatibility complex-bound antigens inherited from tumor lysate-pulsed dendritic cell. When administrated, the surface-bound IL2 is able to guide the nanovesicle to lymphoid organs and activate the IL2 receptor on lymphocytes. Furthermore, it is able to perform antigen presentation in the replacement of professional antigen-presenting cells. This nanovesicle, named IL2-ep13nsEV, induced a strong immune reaction to rescue 50% of the mice in our humanized patient-derived xenografts, sensitized cancer cells to immune checkpoint inhibitor treatment, and prevented the recurrence of resected tumors. This paradigm presents a feasible strategy for the treatment and prevention of metastatic breast cancer.
ISSN:2375-2548
2375-2548
DOI:10.1126/SCIADV.ADE0625